The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
Crossref DOI link: https://doi.org/10.1007/s12325-015-0233-1
Published Online: 2015-09-05
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jha, Ashok
Upton, Alex
Dunlop, William C. N.
Akehurst, Ron
Funding for this research was provided by:
Mundipharma International Limited, Cambridge, UK